Masimo (NASDAQ: MASI) announced today that Masimo is helping
clinicians at Renown Health in Reno, Nevada, to address the
COVID-19 surge, including through use of Masimo SafetyNet™, a
remote patient management platform. Renown Health is using Masimo
SafetyNet to help care for patients positive for COVID-19 recover
at home—and to help notify clinicians of the need to intervene when
patients exhibit signs of deterioration.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201221005159/en/
Masimo SafetyNet™ (Photo: Business
Wire)
Renown Health is a non-profit integrated healthcare network
serving Nevada, Lake Tahoe, and northeast California. Masimo
SafetyNet, introduced earlier this year as part of Masimo’s efforts
to help hospitals and clinicians combat the pandemic, is now in use
at numerous institutions around the world. Renown Health uses
Masimo Patient SafetyNet™ and Masimo Rad-97® Pulse CO-Oximeters® to
provide bedside and remote oxygen saturation and respiratory and
pulse rate monitoring and notification within their hospitals and
at a state-of-the-art 700-bed Alternate Care Facility. The facility
has expanded into an adjacent parking structure, turned into a
makeshift general ward to accommodate the unprecedented surge of
patients suffering from COVID-19. In addition, Renown was one of
the first systems to implement Masimo SafetyNet to expand patient
care from the hospital to the home.
“We at Renown are proud of our national reputation as an
innovator in implementing new models, technology, and systems of
care for the community,” said Tony Slonim, MD, DrPH, President
& CEO. “We are working with some incredible partners, including
Masimo, to transform care and demonstrate value in a way that
appeals to patients and helps clinicians improve outcomes and
reduce costs. Renown’s Hospital-at-Home model of care technology
enables patients to receive hospital-level care in the comfort of
their own homes. This is especially critical for patients who are
elderly, frail or vulnerable to complications.”
“This type of technology is a game-changer in improving patient
care,” said Paul Sierzenski, MD, MSHQS, Chief Medical Officer,
Acute Services, Renown Health. “Given the demand on our hospitals
during this COVID-19 pandemic, we are pleased to provide
appropriate patients with this telehealth solution, which assists
in our management of patients with COVID-19 and allows patients the
convenience of being in their own homes.”
Renown has found particular benefit in using Masimo SafetyNet to
spot possible deterioration in home-based patients’ vital signs and
intervene proactively, before their condition worsens. Dr. David
Lemak, Section Chief for Urgent Care at Renown Medical Group-Ryland
St., heads the team which conducts virtual telehealth visits with
discharged patients. Recently, they noticed several drops in the
oxygen saturation of Jim Cox, a 58-year-old patient who was being
monitored at home as he recovered from COVID-19. Following a
virtual visit with Dr. Lemak, Jim returned to the hospital, where
cardiac complications could be addressed.
“I was excited to be one of the first patients chosen to use the
Masimo SafetyNet ‘hospital-at-home’ technology,” said Jim Cox of
Reno. “The system was easy to use. I was able to monitor my own
vital signs through the app on my cell phone, and was pleased with
the virtual medical visits provided by Dr. Lemak, and the nurses
monitoring my device. It was a relief to be back with my family,
recuperating in my own bed and making my own meals.”
“With Masimo SafetyNet,” said Dr. Lemak, “we have access to
continuous, meaningful data, without burdening our recovering
patients, giving my team confidence that even when they’re not
physically present with us, our patients are in good hands. We’re
so grateful to have been able to help Jim—without this system, the
outcome could have been very different.” Jim added, “While I was at
home, my medical condition did not improve. Without this device and
the Renown staff checking in with me, I probably would have ignored
my symptoms and tried to sleep it off. Instead, I was immediately
admitted back to the hospital.”
“Our patients at Renown have the most sophisticated and reliable
respiratory monitoring available anywhere,” said Jason Farnsworth,
MBA, Director of Respiratory Care Services at Renown. “We know that
physiologic monitoring improves outcomes and saves lives. The
ability to extend that capability to patients in non-traditional
settings and at home during this crisis is transformative. Our
teams are excited to be able to help patients and their families –
and ensure they receive the clinical support they need by using
this technology and monitoring.”
“To know that we can provide quality care for patients
recovering from COVID-19, and help ease their transition back to
their normal lives, where they can recover in the comfort of their
own homes, is fantastic,” said Mitchell Fong, Director of
Telehealth Services at Renown. “Patients have shared that they
enjoy being at home, sitting in their favorite recliner, enjoying a
home-cooked meal and even transitioning back to remote work. If we
can help people feel better, we feel better.”
Joe Kiani, Founder and CEO of Masimo, said, “We are grateful to
be able to partner with institutions like Renown Health to make a
positive difference at this exceptionally difficult time. Like
hospitals and doctors everywhere, Renown is doing their best to
help as many patients as possible, and Masimo SafetyNet allows them
to stretch their resources and keep much-in-demand in-hospital beds
free for the most acute cases, without compromising their ability
to keep track of lower-acuity patients efficiently and effectively
at home. We look forward to continuing to collaborate with Renown
Health in the future as we expand the ways that Masimo SafetyNet
and our other monitoring and automation solutions can help Renown
improve their patient care and outcomes.”
Harnessing its expertise in noninvasive patient monitoring,
automation, and telehealth solutions, Masimo developed Masimo
SafetyNet—which combines hospital-grade tetherless pulse oximetry,
continuous temperature measurement, and a remote data capture and
surveillance platform—to help hospitals accommodate surges in
COVID-19 patient volume and help lower-acuity patients recover at
home and in other alternate care spaces. Masimo SafetyNet allows
clinicians to monitor their patients’ physiological
status—including oxygen saturation, respiration rate, pulse rate,
and temperature—from afar, at all times. Masimo SafetyNet can be
rapidly deployed and easily scaled as needed, without additional
hardware or network infrastructure, helping caregivers provide the
best possible care during this pandemic.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs4-7 Masimo SET® is estimated to be used on more
than 200 million patients in leading hospitals and other healthcare
settings around the world,8 and is the primary pulse oximetry at 9
of the top 10 hospitals according to the 2020-21 U.S. News and
World Report Best Hospitals Honor Roll.9 Masimo continues to refine
SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors
during conditions of motion has been significantly improved,
providing clinicians with even greater confidence that the SpO2
values they rely on accurately reflect a patient’s physiological
status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the
Masimo Hospital Automation™ platform, and include Iris Gateway®,
Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and
Masimo SafetyNet™. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SafetyNet™. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of
which are beyond our control and could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to
our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SafetyNet, contribute to positive
clinical outcomes and patient safety; risks related to our belief
that Masimo noninvasive medical breakthroughs provide
cost-effective solutions and unique advantages; risks related to
COVID-19; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the
SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of today's date. We do not undertake any obligation to update,
amend or clarify these statements or the "Risk Factors" contained
in our most recent reports filed with the SEC, whether as a result
of new information, future events or otherwise, except as may be
required under the applicable securities laws.
About Renown Health
Renown Health is a locally governed and locally owned,
not-for-profit integrated healthcare network serving northern
Nevada, Lake Tahoe and northeast California. Renown is one of the
region’s largest private employers with a workforce of more than
7,000. It comprises three acute care hospitals, a rehabilitation
hospital, the area’s most comprehensive medical group and urgent
care network, and the region’s largest and only locally owned
not-for-profit insurance company, Hometown Health. Renown has a
long tradition and commitment to continually improve the care and
the health of our community. For more information, visit
renown.org.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201221005159/en/
Media Contacts: Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Renown Public Relations 775-691-7308 news@renown.org
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2023 to Mar 2024